1009 related articles for article (PubMed ID: 33561300)
1. Aptamer Blocking Strategy Inhibits SARS-CoV-2 Virus Infection.
Sun M; Liu S; Wei X; Wan S; Huang M; Song T; Lu Y; Weng X; Lin Z; Chen H; Song Y; Yang C
Angew Chem Int Ed Engl; 2021 Apr; 60(18):10266-10272. PubMed ID: 33561300
[TBL] [Abstract][Full Text] [Related]
2. A SARS-CoV-2 Spike Binding DNA Aptamer that Inhibits Pseudovirus Infection by an RBD-Independent Mechanism*.
Schmitz A; Weber A; Bayin M; Breuers S; Fieberg V; Famulok M; Mayer G
Angew Chem Int Ed Engl; 2021 Apr; 60(18):10279-10285. PubMed ID: 33683787
[TBL] [Abstract][Full Text] [Related]
3. Neutralizing Aptamers Block S/RBD-ACE2 Interactions and Prevent Host Cell Infection.
Liu X; Wang YL; Wu J; Qi J; Zeng Z; Wan Q; Chen Z; Manandhar P; Cavener VS; Boyle NR; Fu X; Salazar E; Kuchipudi SV; Kapur V; Zhang X; Umetani M; Sen M; Willson RC; Chen SH; Zu Y
Angew Chem Int Ed Engl; 2021 Apr; 60(18):10273-10278. PubMed ID: 33684258
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
5. Xeno-Nucleic Acid (XNA) 2'-Fluoro-Arabino Nucleic Acid (FANA) Aptamers to the Receptor-Binding Domain of SARS-CoV-2 S Protein Block ACE2 Binding.
Alves Ferreira-Bravo I; DeStefano JJ
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696413
[TBL] [Abstract][Full Text] [Related]
6. A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry.
Valero J; Civit L; Dupont DM; Selnihhin D; Reinert LS; Idorn M; Israels BA; Bednarz AM; Bus C; Asbach B; Peterhoff D; Pedersen FS; Birkedal V; Wagner R; Paludan SR; Kjems J
Proc Natl Acad Sci U S A; 2021 Dec; 118(50):. PubMed ID: 34876524
[TBL] [Abstract][Full Text] [Related]
7. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry.
Shin YH; Jeong K; Lee J; Lee HJ; Yim J; Kim J; Kim S; Park SB
Angew Chem Int Ed Engl; 2022 Mar; 61(11):e202115695. PubMed ID: 35043545
[TBL] [Abstract][Full Text] [Related]
9. Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides.
Freitas FC; Ferreira PHB; Favaro DC; Oliveira RJ
J Chem Inf Model; 2021 Mar; 61(3):1226-1243. PubMed ID: 33619962
[TBL] [Abstract][Full Text] [Related]
10. Repositioning of histamine H
Ge S; Wang X; Hou Y; Lv Y; Wang C; He H
Eur J Pharmacol; 2021 Apr; 896():173897. PubMed ID: 33497607
[TBL] [Abstract][Full Text] [Related]
11. Targeting SARS-CoV-2 Spike Protein/ACE2 Protein-Protein Interactions: a Computational Study.
Pirolli D; Righino B; De Rosa MC
Mol Inform; 2021 Jun; 40(6):e2060080. PubMed ID: 33904240
[TBL] [Abstract][Full Text] [Related]
12. Advances in Magnetic Microbead Affinity Selection Screening: Discovery of Natural Ligands to the SARS-CoV-2 Spike Protein.
Muchiri RN; Kibitel J; Redick MA; van Breemen RB
J Am Soc Mass Spectrom; 2022 Jan; 33(1):181-188. PubMed ID: 34939787
[TBL] [Abstract][Full Text] [Related]
13. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
[TBL] [Abstract][Full Text] [Related]
14. Potential antiviral activity of isorhamnetin against SARS-CoV-2 spike pseudotyped virus in vitro.
Zhan Y; Ta W; Tang W; Hua R; Wang J; Wang C; Lu W
Drug Dev Res; 2021 Dec; 82(8):1124-1130. PubMed ID: 33847382
[TBL] [Abstract][Full Text] [Related]
15. Identification of SARS-CoV-2-against aptamer with high neutralization activity by blocking the RBD domain of spike protein 1.
Yang G; Li Z; Mohammed I; Zhao L; Wei W; Xiao H; Guo W; Zhao Y; Qu F; Huang Y
Signal Transduct Target Ther; 2021 Jun; 6(1):227. PubMed ID: 34112756
[No Abstract] [Full Text] [Related]
16. A potential antiviral activity of Esculentoside A against binding interactions of SARS-COV-2 spike protein and angiotensin converting enzyme 2 (ACE2).
Zeng MS; Yu WD; Wang HX; Liu JY; Xu PP
Int J Biol Macromol; 2021 Jul; 183():2248-2261. PubMed ID: 34111482
[TBL] [Abstract][Full Text] [Related]
17. Tinocordiside from
Balkrishna A; Pokhrel S; Varshney A
Comb Chem High Throughput Screen; 2021; 24(10):1795-1802. PubMed ID: 33172372
[TBL] [Abstract][Full Text] [Related]
18. Specific delivering of RNAi using Spike's aptamer-functionalized lipid nanoparticles for targeting SARS-CoV-2: A strong anti-Covid drug in a clinical case study.
Saify Nabiabad H; Amini M; Demirdas S
Chem Biol Drug Des; 2022 Feb; 99(2):233-246. PubMed ID: 34714580
[TBL] [Abstract][Full Text] [Related]
19. Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction.
Brown EEF; Rezaei R; Jamieson TR; Dave J; Martin NT; Singaravelu R; Crupi MJF; Boulton S; Tucker S; Duong J; Poutou J; Pelin A; Yasavoli-Sharahi H; Taha Z; Arulanandam R; Surendran A; Ghahremani M; Austin B; Matar C; Diallo JS; Bell JC; Ilkow CS; Azad T
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668756
[TBL] [Abstract][Full Text] [Related]
20. Catechin and curcumin interact with S protein of SARS-CoV2 and ACE2 of human cell membrane: insights from computational studies.
Jena AB; Kanungo N; Nayak V; Chainy GBN; Dandapat J
Sci Rep; 2021 Jan; 11(1):2043. PubMed ID: 33479401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]